CTLA4 Inhibition Reverses KEAP1/STK11-Associated Resistance to Anti-PD-(L)1 Available to Purchase

Major Finding: CTLA4 inhibition overcomes STK11/KEAP1 mutation-driven resistance to anti PD-(L)1 immunotherapy.
Concept: Dual CTLA4/PD-(L)1 blockade engages CD4⁺ T cells and antitumor myeloid cells to hinder tumor growth.
Impact: Patients with STK11/KEAP1-mutant lung cancer, in particular, may benefit from dual immunotherapy.